ALVO

Alvotech

5.00

Oct 16 • 3:59 PM ET -0.31 (-5.84%)

5.00

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic Luxembourg Small NASD

Peers: AMRX BHC PRGO TEVA VTRS INDV KNSA ALKS LNTH TLX

| Held by: IBB IDNA EWX PRFZ IBBQ GLCR BIB

Scroll to Statements

Index	-
Market Cap	1.95B
Enterprise Value	3.26B
Income	-179.59M
Sales	491.95M
Book/sh	-0.54
Cash/sh	0.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1460
IPO	Nov 09, 2020

P/E	-
Forward P/E	21.96
PEG	-
P/S	3.97
P/B	-
P/C	13.68
P/FCF	-
EV/EBITDA	37.84
EV/Sales	6.63
Quick Ratio	0.96
Current Ratio	1.65
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.56
EPS next Y	0.23
EPS next Q	-0.02
EPS this Y	80.57%
EPS next Y	1271.79%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	91.85% -
EPS Y/Y TTM	-365.51%
Sales Y/Y TTM	-12.17%
EPS Q/Q	-276.37%
Sales Q/Q	-38.94%
Earnings	Aug 19 AMC
EPS/Sales Surpr.	-62.17% 2.91%

Insider Own	55.53%
Insider Trans	0.00%
Inst Own	11.05%
Inst Trans	8.10%
ROA	-12.05%
ROE	-
ROIC	-14.88%
Gross Margin	60.45%
Oper. Margin	9.12%
Profit Margin	-36.51%
SMA20	-12.29%
SMA50	-2.68%
SMA200	18.81%
Trades

Shs Outstand	356.82M
Shs Float	173.61M
Short Float	3.66%
Short Ratio	5.92
Short Interest	6.35M
52W High	9.00 -44.44%
52W Low	2.94 70.07%
Volatility	6.72% 5.84%
ATR (14)	0.33
RSI (14)	41.01
Beta	0.21
Rel Volume	0.99
Avg Volume	1.07M
Volume	1,059,087

Perf Week	-13.49%
Perf Month	-6.37%
Perf Quarter	46.63%
Perf Half Y	38.50%
Perf YTD	-2.53%
Perf Year	-42.86%
Perf 3Y	-44.69%
Perf 5Y	-49.08%
Perf 10Y	-
Recom	1.38
Target Price	6.96
Prev Close	5.31
Price	5.00
Change %	-5.84%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-26	Upgrade	Barclays	Underweight → Overweight	$8
Aug-24-26	Initiated	BofA Securities	Buy	$7
Aug-14-26	Initiated	Evercore ISI	Outperform
Dec-09-25	Initiated	Barclays	Underweight	$5
Nov-04-25	Downgrade	Deutsche Bank	Buy → Hold	$8
Oct-14-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$14
Sep-23-25	Upgrade	Deutsche Bank	Hold → Buy	$14
Feb-14-25	Initiated	UBS	Buy	$18
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $17
Oct-20-23	Upgrade	Citigroup	Sell → Neutral	$5 → $10
Sep-21-23	Initiated	Barclays	Equal Weight	$10
Sep-07-22	Initiated	Morgan Stanley	Equal-Weight	$10
Sep-06-22	Downgrade	Citigroup	Buy → Sell	$12 → $5
Jul-26-22	Initiated	Citigroup	Buy	$12

Show Previous Ratings

Oct-14-26 04:30AM	Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea 8 mg (GlobeNewswire)
Oct-06-26 04:37PM	Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply (GlobeNewswire)
Oct-05-26 03:14PM	Alvotech Soars 13% on FDA Nod That Effectively Doubles US Humira Biosimilar Capacity (TIKR) +12.11%
11:21AM	Alvotech stock surges after FDA manufacturing approval (Investing.com)
04:00AM	FDA approves additional U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira (GlobeNewswire)
02:33PM	Loading…
Sep-16-26 02:33PM	ALVO Stock Jumps On Double Upgrade Why Barclays Sees A 59% Upside (Stocktwits)
06:53AM	Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target (InvestorsHub)
Aug-31-26 04:30AM	Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio to Subcutaneous Presentations (GlobeNewswire)
Aug-27-26 08:00AM	Alvotech to present at upcoming investor conferences in September (GlobeNewswire)
Aug-24-26 06:41AM	BofA starts bullish Alvotech coverage on biosimilar launch cycle (Investing.com) +18.51%
Aug-21-26 09:00AM	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets (GlobeNewswire)
Aug-20-26 08:30AM	Alvotech Q2 2026 Earnings Call Summary (Moby) +7.02%
Aug-19-26 04:30PM	Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update (GlobeNewswire)
09:18AM	Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 461% Upside (GuruFocus.com)
Aug-18-26 09:18AM	Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 471% Upside (GuruFocus.com)
08:00AM	Loading…
Aug-10-26 08:00AM	Alvotech to Report Financial Results for H1 2026 (GlobeNewswire)
Jul-29-26 09:32AM	Alvotech announces successful closure of FDA inspection of manufacturing facility (GlobeNewswire) +13.87%
Jul-03-26 04:01PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
Jul-01-26 04:00AM	Alvotech further strengthens liquidity by securing term loan facility of $75 million (GlobeNewswire)
Jun-22-26 06:48PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire) -6.89%
Jun-18-26 05:51AM	Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement (GlobeNewswire)
04:00AM	Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares (GlobeNewswire)
Jun-15-26 11:59PM	Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement (GlobeNewswire) -8.73%
04:01PM	Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares (GlobeNewswire)
Jun-10-26 04:30PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
Jun-08-26 06:41AM	Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO) (InvestorsHub) +19.77%
04:00AM	Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (GlobeNewswire)
Jun-04-26 04:00AM	Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea (GlobeNewswire) +19.11%
Jun-03-26 04:30PM	Main Results of 2026 Annual and Extraordinary General Meeting (GlobeNewswire)
Jun-02-26 04:30PM	Alvotech to present at upcoming investor conferences in June (GlobeNewswire) -6.83%
04:30AM	Loading…
Jun-01-26 04:30AM	Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland (GlobeNewswire)
May-11-26 04:30AM	Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility (GlobeNewswire) +10.12%
May-06-26 04:30PM	Alvotech Q1 2026 Financial Results (GlobeNewswire) -10.36%
09:27AM	Earnings To Watch: Alvotech (ALVO) Reports Q1 2026 Result (GuruFocus.com)
Apr-30-26 04:30PM	Alvotech Announces a Change in its Executive Team (GlobeNewswire)
Apr-24-26 08:30AM	Alvotech to Report Financial Results for the First Quarter of 2026 (GlobeNewswire)
Mar-30-26 07:58PM	Alvotech files Annual Report with the SEC (GlobeNewswire) +5.79%
07:55PM	Alvotech Publishes 2025 Annual Report (GlobeNewswire)
Mar-18-26 06:15PM	Alvotech Q4 2025 and Full Year 2025 Financial Results (GlobeNewswire) -5.79%
09:18AM	Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Mar-17-26 09:18AM	Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +5.82%
Mar-04-26 03:00AM	Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-26-26 04:00PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire)
Feb-15-26 04:08AM	Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80 (Insider Monkey)
Feb-11-26 11:00AM	Alvotech Announces Increase in Number of Own Shares (GlobeNewswire) -6.73%
Feb-05-26 03:00AM	Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio (GlobeNewswire)
Feb-04-26 01:39PM	Alvotech (ALVO): A Bull Case Theory (Insider Monkey)
Feb-02-26 03:00AM	Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates (GlobeNewswire)
Jan-29-26 03:00AM	Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg (GlobeNewswire)
Jan-22-26 09:26AM	Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y (Zacks)
Jan-16-26 08:52AM	ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? (Zacks)
Jan-09-26 03:16AM	Alvotech (ALVO) Secures $100 Million in New Financing (Insider Monkey)
Jan-07-26 05:00PM	Correction: Transactions of Managers and Closely Associated Persons (GlobeNewswire)
Jan-06-26 03:00PM	Transactions of Managers and Closely Associated Persons (GlobeNewswire) -6.53%
07:15AM	Alvotech announces planned CEO succession and leadership transition (GlobeNewswire)
Dec-31-25 04:30PM	Alvotech Secures Term Loan Facility of USD 100 Million (GlobeNewswire)
Dec-29-25 02:40PM	Changes in company's own shares (GlobeNewswire) -5.51%
Dec-22-25 03:26PM	Alvotech's Financial Calendar for 2026 (GlobeNewswire)
02:00AM	Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma (GlobeNewswire)
Dec-21-25 09:03AM	Alvotech (ALVO): Firm Reaffirms 2025 Growth Outlook (Insider Monkey)
Dec-19-25 03:30AM	Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea (GlobeNewswire)
Dec-17-25 02:30AM	Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering (GlobeNewswire)
Dec-16-25 11:48AM	Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance (GlobeNewswire) -6.67%
Dec-11-25 09:30AM	Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman (PR Newswire)
Dec-05-25 05:06AM	New Strong Sell Stocks for Dec.5 (Zacks) +7.89%
Dec-04-25 01:39PM	Alvotech (ALVO): A Bull Case Theory (Insider Monkey) +9.27%
Dec-02-25 08:10PM	Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman (PR Newswire)
Nov-28-25 03:59AM	New Strong Sell Stocks for Nov. 28 (Zacks)
Nov-24-25 08:01PM	Alvotech (ALVO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Regulatory Challenges (GuruFocus.com) +6.42%
05:30AM	Alvotech Announces Approval of AVT03, a Biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area (GlobeNewswire)
Nov-21-25 05:27AM	New Strong Sell Stocks for Nov. 21st (Zacks)
05:10AM	Alvotech and Advanz announce EC approval for Gobivaz biosimilar (Pharmaceutical Business Review)
Nov-20-25 04:00AM	Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) (GlobeNewswire)
Nov-13-25 09:06AM	Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman (PR Newswire)
04:59AM	New Strong Sell Stocks for Nov. 13 (Zacks)
Nov-12-25 05:55PM	Alvotech (ALVO) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:40PM	Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update (GlobeNewswire)
07:20AM	Earnings To Watch: Alvotech (ALVO) Reports Q3 2025 Result (GuruFocus.com)
Nov-11-25 07:23AM	Alvotech (ALVO) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-10-25 04:00AM	UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea (aflibercept) (GlobeNewswire)
Nov-07-25 08:10AM	Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +12.85%
05:20AM	Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz (Pharmaceutical Business Review)
Nov-06-25 09:07AM	Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz, a Biosimilar to Simponi (golimumab), from the MHRA (GlobeNewswire)
08:30AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 10:00AM	Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:15AM	X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 04:01PM	Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update (GlobeNewswire)
02:00AM	Alvotech faces FDA setback for its Simponi biosimilar AVT05 (Pharmaceutical Technology)
Nov-02-25 05:12PM	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 (GlobeNewswire)
Oct-27-25 11:32AM	Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues (Zacks)
Oct-22-25 05:00AM	Alvotech Announces Changes in Global Business Development and Commercial Operations Team (GlobeNewswire)
Oct-21-25 03:53AM	Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength? (Zacks)
Oct-15-25 09:55AM	Wall Street Analysts See a 105.88% Upside in Alvotech (ALVO): Can the Stock Really Move This High? (Zacks) +5.65%
Oct-09-25 10:19AM	Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-06-25 08:00AM	Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR (omalizumab) (Business Wire)
04:40AM	European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency (GlobeNewswire)
Sep-30-25 09:15AM	Here's How Alvotech is Expanding its Portfolio Beyond Immunology (Zacks)
Sep-24-25 03:42AM	Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains? (Zacks)
Sep-23-25 12:19PM	Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play? (Zacks) +8.61%
Sep-22-25 06:15AM	European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia and Xgeva (GlobeNewswire)

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Founder & Executive ChairmanMr. Vilhelm Robert Wessman

Chief Executive OfficerMs. Lisa Graver

Chief Financial OfficerMs. Linda Jonsdottir

Chief Operating OfficerMr. Joseph E. McClellan

Chief Information OfficerMs. Neha Patel

ALVO

Alvotech

Upgrade your Finviz experience